Johnson & Johnson raised its full-year forecast after exceeding second-quarter Wall Street expectations.
The company reported $25.3 billion in revenue. Adjusted earnings reached $2.90 per share.
The Innovative Medicine division drove growth as sales for Tremfya and Darzalex beat projections.
The MedTech unit underperformed with $8.93 billion in sales, missing the $8.97 billion analyst estimate. Abiomed heart pump sales fell 2% due to lower U.S. procedure volumes.